FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799675510> ?p ?o ?g. }

• W2799675510 endingPage "30" @default.
• W2799675510 startingPage "23" @default.
• W2799675510 abstract "Objective We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. Methods We used a standard 3 + 3 dose-escalation design with doxorubicin 1.5 mg/m2, cisplatin 7.5 mg/m2 q 4 to 6 weeks for 3 cycles and subsequent dose escalation steps (20% increment per step) in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Toxicity and clinical efficacy were monitored. The primary endpoint was the maximum-tolerable dose. Secondary endpoints included histologic tumor regression and serum parameters. Results 15 evaluable patients (3, 7, and 5 in cohorts 1, 2, and 3, respectively) on average received 2.3 PIPAC cycles. No dose limiting toxicities were found. Adverse side effects were 1 grade 3 event (colon perforation) and 85 grade 1/2 events including fatigue (n = 19), abdominal pain (n = 18), nausea/vomiting (n = 14), sleep disorder (n = 8), diarrhea (n = 5), and fever (n = 2). Liver and renal toxicity was not observed in any of the 3 cohorts (AST 19.1 ± 3.2, 25.8 ± 6.5, and 22.1 ± 4.5 IU/L, respectively; ALT 14.7 ± 3.5, 18.5 ± 5.6, and 23.3 ± 13.0 IU/L, respectively; GGT 45.7 ± 35.1, 25.2 ± 10.3, and 43.9 ± 26.4 IU/L, respectively; serum creatinine 1.06 ± 0.23, 0.80 ± 0.17, and 0.89 ± 0.35 mg/dL, respectively). No systemic hematologic toxicity, alopecia, or neurotoxicity was noted. The maximum tolerable dose was not reached. Histologic tumor regression was observed in 7/11 (64%) patients who underwent ≥2 PIPAC cycles. Conclusions PIPAC with cisplatin and doxorubicin may be safely used at an intraperitoneal dose of 10.5 mg/m2 and 2.1 mg/m2, respectively. Systemic toxicity of this therapy is low." @default.
• W2799675510 created "2018-05-17" @default.
• W2799675510 creator A5014215305 @default.
• W2799675510 creator A5041520697 @default.
• W2799675510 creator A5044518039 @default.
• W2799675510 creator A5058035345 @default.
• W2799675510 creator A5058235988 @default.
• W2799675510 creator A5087812132 @default.
• W2799675510 date "2018-07-01" @default.
• W2799675510 modified "2023-09-27" @default.
• W2799675510 title "A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis" @default.
• W2799675510 cites W1972001844 @default.
• W2799675510 cites W1980661013 @default.
• W2799675510 cites W1989201927 @default.
• W2799675510 cites W1990342299 @default.
• W2799675510 cites W1994039819 @default.
• W2799675510 cites W2051099595 @default.
• W2799675510 cites W2054485301 @default.
• W2799675510 cites W2056808442 @default.
• W2799675510 cites W2078639676 @default.
• W2799675510 cites W2080853165 @default.
• W2799675510 cites W2087230876 @default.
• W2799675510 cites W2093274439 @default.
• W2799675510 cites W2115499099 @default.
• W2799675510 cites W2118548073 @default.
• W2799675510 cites W2124695217 @default.
• W2799675510 cites W2133768270 @default.
• W2799675510 cites W2162553170 @default.
• W2799675510 cites W2528228811 @default.
• W2799675510 cites W2567965265 @default.
• W2799675510 cites W2590370975 @default.
• W2799675510 cites W2605456582 @default.
• W2799675510 cites W2605936377 @default.
• W2799675510 cites W2737389832 @default.
• W2799675510 cites W2766777872 @default.
• W2799675510 doi "https://doi.org/10.1016/j.ygyno.2018.05.001" @default.
• W2799675510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29743140" @default.
• W2799675510 hasPublicationYear "2018" @default.
• W2799675510 type Work @default.
• W2799675510 sameAs 2799675510 @default.
• W2799675510 citedByCount "61" @default.
• W2799675510 countsByYear W27996755102018 @default.
• W2799675510 countsByYear W27996755102019 @default.
• W2799675510 countsByYear W27996755102020 @default.
• W2799675510 countsByYear W27996755102021 @default.
• W2799675510 countsByYear W27996755102022 @default.
• W2799675510 countsByYear W27996755102023 @default.
• W2799675510 crossrefType "journal-article" @default.
• W2799675510 hasAuthorship W2799675510A5014215305 @default.
• W2799675510 hasAuthorship W2799675510A5041520697 @default.
• W2799675510 hasAuthorship W2799675510A5044518039 @default.
• W2799675510 hasAuthorship W2799675510A5058035345 @default.
• W2799675510 hasAuthorship W2799675510A5058235988 @default.
• W2799675510 hasAuthorship W2799675510A5087812132 @default.
• W2799675510 hasConcept C121608353 @default.
• W2799675510 hasConcept C126322002 @default.
• W2799675510 hasConcept C126894567 @default.
• W2799675510 hasConcept C141071460 @default.
• W2799675510 hasConcept C197934379 @default.
• W2799675510 hasConcept C203092338 @default.
• W2799675510 hasConcept C2776694085 @default.
• W2799675510 hasConcept C2778239845 @default.
• W2799675510 hasConcept C2780427987 @default.
• W2799675510 hasConcept C2780580376 @default.
• W2799675510 hasConcept C2780852908 @default.
• W2799675510 hasConcept C2780955771 @default.
• W2799675510 hasConcept C29730261 @default.
• W2799675510 hasConcept C535046627 @default.
• W2799675510 hasConcept C71924100 @default.
• W2799675510 hasConcept C90924648 @default.
• W2799675510 hasConceptScore W2799675510C121608353 @default.
• W2799675510 hasConceptScore W2799675510C126322002 @default.
• W2799675510 hasConceptScore W2799675510C126894567 @default.
• W2799675510 hasConceptScore W2799675510C141071460 @default.
• W2799675510 hasConceptScore W2799675510C197934379 @default.
• W2799675510 hasConceptScore W2799675510C203092338 @default.
• W2799675510 hasConceptScore W2799675510C2776694085 @default.
• W2799675510 hasConceptScore W2799675510C2778239845 @default.
• W2799675510 hasConceptScore W2799675510C2780427987 @default.
• W2799675510 hasConceptScore W2799675510C2780580376 @default.
• W2799675510 hasConceptScore W2799675510C2780852908 @default.
• W2799675510 hasConceptScore W2799675510C2780955771 @default.
• W2799675510 hasConceptScore W2799675510C29730261 @default.
• W2799675510 hasConceptScore W2799675510C535046627 @default.
• W2799675510 hasConceptScore W2799675510C71924100 @default.
• W2799675510 hasConceptScore W2799675510C90924648 @default.
• W2799675510 hasIssue "1" @default.
• W2799675510 hasLocation W27996755101 @default.
• W2799675510 hasLocation W27996755102 @default.
• W2799675510 hasOpenAccess W2799675510 @default.
• W2799675510 hasPrimaryLocation W27996755101 @default.
• W2799675510 hasRelatedWork W2081557631 @default.
• W2799675510 hasRelatedWork W2111792237 @default.
• W2799675510 hasRelatedWork W2361753312 @default.
• W2799675510 hasRelatedWork W2375265431 @default.
• W2799675510 hasRelatedWork W2377198612 @default.
• W2799675510 hasRelatedWork W2387364079 @default.
• W2799675510 hasRelatedWork W2412619742 @default.

• next